Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph not_applicable
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingnot_applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NCT06353646
not_yet_recruitingnot_applicable

XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer

NCT07114666

Clinical Trials (2)

Showing 2 of 2 trials
NCT06353646Not Applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Recruiting
NCT07114666Not Applicable

XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2